Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNOREK)

Drug Name
ML315 Drug Info
Synonyms
ML315; CHEMBL1885748; 1440251-53-5; MLS004256649; GTPL8162; KUC107550N; BDBM50435474; ML 315; AKOS032952995; KSC-14-101; NCGC00241342-01; NCGC00241342-02; SMR003081704; BRD-K98168317-001-01-9; 5-(benzo[d][1,3]dioxol-5-yl)-N-(3,5-dichlorobenzyl)pyrimidin-4-amine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
46926514
TTD Drug ID
DMNOREK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting CDC-like kinase 1 (CLK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TG003 DMP4HR2 Discovery agent N.A. Patented [2]
leucettine L41 DMBYND6 Discovery agent N.A. Investigative [3]
PMID23642479C17 DM4JWMA Discovery agent N.A. Investigative [1]
KH-CB19 DMSOB3U Discovery agent N.A. Investigative [4]
Drug(s) Targeting CDC-like kinase 2 (CLK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TG003 DMP4HR2 Discovery agent N.A. Patented [2]
PMID23642479C17 DM4JWMA Discovery agent N.A. Investigative [1]
Drug(s) Targeting Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Harmine DMPA5WD Discovery agent N.A. Patented [5]
PMID28766366-Compound-Scheme21Left DMWTRUK N. A. N. A. Patented [5]
PMID28766366-Compound-Scheme21Right DMF3X40 N. A. N. A. Patented [5]
PMID28766366-Compound-Scheme14BINDY DMBQ0RN N. A. N. A. Patented [5]
TG003 DMP4HR2 Discovery agent N.A. Patented [5]
PMID28766366-Compound-Scheme2WO2012/098065bottom DMO4Q95 N. A. N. A. Patented [5]
PMID28766366-Compound-Scheme16DMAT DMQ5UEA N. A. N. A. Patented [5]
PMID28766366-Compound-Scheme7WO2012/098070upper DMGAQR5 N. A. N. A. Patented [5]
PMID28766366-Compound-Scheme9EHT1610 DMMZGC8 N. A. N. A. Patented [5]
PMID28766366-Compound-Scheme9EHT5372 DM0O18N N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting CDC-like kinase 4 (CLK4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23642479C17 DM4JWMA Discovery agent N.A. Investigative [1]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CDC-like kinase 1 (CLK1) TTE6YDG CLK1_HUMAN Inhibitor [1]
CDC-like kinase 2 (CLK2) TT85TPS CLK2_HUMAN Inhibitor [1]
CDC-like kinase 4 (CLK4) TT1RFQP CLK4_HUMAN Inhibitor [1]
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) TTSBVFO DYR1A_HUMAN Inhibitor [1]

References

1 Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
2 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
3 Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
4 Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.
5 Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.